Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.
Mar N, Zakharia Y, Falcon A, Morales-Barrera R, Mellado B, Duran I, Oh DY, Williamson SK, Gajate P, Arkenau HT, Jones RJ, Teo MY, Turan T, McLaughlin RT, Peltier HM, Chong E, Atluri H, Dean JP, Castellano D. Mar N, et al. Among authors: teo my. Cancers (Basel). 2023 May 30;15(11):2978. doi: 10.3390/cancers15112978. Cancers (Basel). 2023. PMID: 37296940 Free PMC article.
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L, Powles T, Carril-Ajuria L, Castellano D, Velho PI, Hahn NM, McKay RR, Raggi D, Necchi A, Kanesvaran R, Alerasool P, Gaines J, Galsky M, Bellmunt J, Sonpavde G. Wei XX, et al. Among authors: teo my. J Urol. 2021 Feb;205(2):414-419. doi: 10.1097/JU.0000000000001371. Epub 2020 Sep 16. J Urol. 2021. PMID: 32935617 Free PMC article.
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S. Grivas P, et al. Among authors: teo my. BMC Cancer. 2021 May 24;21(1):593. doi: 10.1186/s12885-021-08085-z. BMC Cancer. 2021. PMID: 34030643 Free PMC article. Clinical Trial.
Nivolumab for the treatment of urothelial cancers.
Teo MY, Rosenberg JE. Teo MY, et al. Expert Rev Anticancer Ther. 2018 Mar;18(3):215-221. doi: 10.1080/14737140.2018.1432357. Epub 2018 Jan 31. Expert Rev Anticancer Ther. 2018. PMID: 29363363 Review.
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Sarfaty M, Whiting K, Teo MY, Lee CH, Peters V, Durocher J, Regazzi AM, McCoy AS, Hettich G, Jungbluth AA, Al-Ahmadie H, Ostrovnaya I, Chaim J, Bajorin DF, Rosenberg JE, Iyer G, Funt SA. Sarfaty M, et al. Among authors: teo my. Cancer Med. 2021 Feb;10(3):1074-1083. doi: 10.1002/cam4.3699. Epub 2020 Dec 31. Cancer Med. 2021. PMID: 33382520 Free PMC article. Clinical Trial.
Treatment of Advanced Prostate Cancer.
Teo MY, Rathkopf DE, Kantoff P. Teo MY, et al. Annu Rev Med. 2019 Jan 27;70:479-499. doi: 10.1146/annurev-med-051517-011947. Annu Rev Med. 2019. PMID: 30691365 Free PMC article. Review.
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
Reis H, Serrette R, Posada J, Lu V, Chen YB, Gopalan A, Fine SW, Tickoo SK, Sirintrapun SJ, Iyer G, Funt SA, Teo MY, Rosenberg JE, Bajorin DF, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA. Reis H, et al. Among authors: teo my. Am J Surg Pathol. 2019 Jul;43(7):920-927. doi: 10.1097/PAS.0000000000001264. Am J Surg Pathol. 2019. PMID: 31135485 Free PMC article.
93 results